Liberate Bio Strengthens Position in In Vivo CAR-M Therapy with Key Patent Licenses
Berlin, Germany – Liberate Bio has secured exclusive and non-exclusive licenses for patents covering chimeric antigen receptor (CAR) designs specifically tailored for myeloid cells – including monocytes and macrophages. This strategic move, announced earlier this week, significantly bolsters the company’s efforts to advance its innovative in vivo CAR-M therapies, a promising new approach to immune reprogramming. The licenses, sourced from Carisma Therapeutics and the University of Pennsylvania, encompass methods and constructs engineered for optimal function within these crucial immune cell populations. This development positions Liberate Bio at the forefront of a rapidly evolving field with the potential to revolutionize treatment for a range of diseases, from autoimmune disorders to cancer.
The significance of this licensing agreement lies in the unique characteristics of myeloid cells. Unlike T cells, which are the primary focus of traditional CAR-T cell therapy, myeloid cells – monocytes, macrophages, and dendritic cells – play a different role in the immune system. They are involved in innate immunity, inflammation, and tissue repair. CAR-T therapy involves modifying a patient’s own T cells to target and destroy cancer cells, but it can be complex and associated with significant side effects. In vivo CAR-M therapy, aims to reprogram these myeloid cells directly within the body, offering a potentially safer and more scalable alternative. According to Liberate Bio, their approach focuses on safely and efficiently reprogramming these cells at scale.
Optimized CAR Designs and LNP Delivery
The newly acquired intellectual property complements Liberate Bio’s existing lipid nanoparticle (LNP) delivery platform. LNPs are tiny spheres of fat that can encapsulate and deliver therapeutic molecules, such as mRNA encoding for CARs, directly to target cells. Liberate Bio’s LNP technology is designed for selective programming of macrophages and monocytes in vivo, meaning within the living organism. This targeted delivery is crucial for maximizing therapeutic efficacy and minimizing off-target effects. The combination of optimized CAR-sequence intellectual property and cell-selective LNP technology allows for a highly integrated approach to in vivo cell therapy.
The company’s Raptor platform plays a critical role in this process. Raptor conducts direct screening of LNPs in non-human primates, allowing Liberate Bio to identify delivery vehicles specifically designed to target extrahepatic – meaning outside the liver – immune cells. Here’s particularly important as many diseases affect tissues and organs beyond the liver. In preclinical studies, Liberate Bio has demonstrated the power of its LNP technology, reporting that its lead LNP candidate resulted in over 99% depletion of circulating B cells in non-human primates by selectively programming monocytes and macrophages. Business Wire reported on this achievement, highlighting the potential for precise immune modulation.
Expert Perspectives and Future Outlook
Walter Strapps, Chief Scientific Officer at Liberate Bio, emphasized the importance of this licensing agreement, stating, “This licensing agreement meaningfully strengthens our clinical programmes. Myeloid cells have unique biology distinct from T cells, and CAR constructs optimised for their activation and persistence are essential.” He further explained that combining validated CAR designs with their myeloid-selective LNP platform is building a differentiated and highly integrated approach to in vivo cell therapy.
Shawn Davis, CEO of Liberate Bio, echoed this sentiment, stating, “In vivo CAR-M represents a new chapter in immune reprogramming. By uniting best-in-class delivery with optimised myeloid CAR designs, we are establishing a durable foundation for a scalable and potentially safer alternative to CAR-T — one capable of reaching broader patient populations across autoimmune and oncology indications.” Pharmaceutical Technology also reported on these statements, underscoring the company’s vision for the future of immune therapy.
Advancing Towards Clinical Trials
Liberate Bio is now focused on progressing its initial in vivo CAR-M candidate into investigational new drug (IND)-enabling studies. The company anticipates initiating clinical evaluation through an investigator-initiated trial in the latter half of 2026. This timeline represents a significant step forward in bringing this innovative therapy to patients. The IND-enabling studies will involve rigorous testing to ensure the safety and efficacy of the therapy before it can be administered to humans. The investigator-initiated trial will likely focus on a specific disease indication where in vivo CAR-M therapy has the potential to offer a significant benefit.
Understanding CAR-M Therapy and its Potential
Chimeric antigen receptor (CAR) therapy involves genetically engineering immune cells to express a receptor that recognizes a specific target on cancer cells or other diseased cells. Although CAR-T therapy has shown remarkable success in treating certain blood cancers, it faces challenges in treating solid tumors and can cause severe side effects, such as cytokine release syndrome. CAR-M therapy aims to overcome these limitations by targeting myeloid cells, which are more abundant and accessible than T cells, and by delivering the CAR directly to the cells in vivo, potentially reducing the risk of severe side effects.
The potential applications of in vivo CAR-M therapy extend beyond oncology. Myeloid cells play a critical role in autoimmune diseases, where the immune system mistakenly attacks the body’s own tissues. By reprogramming these cells, it may be possible to restore immune tolerance and alleviate symptoms of autoimmune disorders. CAR-M therapy could be used to modulate the immune response in infectious diseases and to promote tissue repair after injury.
Liberate Bio’s advancements represent a significant step forward in the field of immune therapy. The company’s innovative approach, combining optimized CAR designs with targeted LNP delivery, holds the promise of a safer, more scalable, and more effective treatment option for a wide range of diseases. The progress towards clinical trials in the latter half of 2026 will be closely watched by the medical community and patients alike.
The company will be presenting further data and updates at upcoming scientific conferences. Readers interested in learning more about Liberate Bio and its in vivo CAR-M therapy platform are encouraged to visit the company’s website for the latest information. The field of in vivo CAR-M therapy is rapidly evolving, and Liberate Bio is poised to be a key player in shaping its future.
What’s Next: Liberate Bio anticipates submitting its IND application in early 2026, paving the way for the initiation of a Phase 1 clinical trial later that year. Stay tuned to World Today Journal for ongoing coverage of this exciting development.
Do you have thoughts on the potential of in vivo CAR-M therapy? Share your comments below, and please share this article with your network.
Worth a look